REGN Regeneron Pharmaceuticals, Inc.
Platform & Compounding FCF
B- 62.7 / 100 composite

AlphaQuality composite grade, weighted for platform & compounding fcf businesses.

Profitability

Weight: 25%
C 55
  • 5yr Avg ROIC 14.5%
  • Operating Margin Trend -7.76 pp/yr

Capital Efficiency

Weight: 15%
A- 81
  • 5yr Avg ROE 16.2%
  • 5yr Share-Count CAGR -0.8%

Growth Quality

Weight: 25%
F 22
  • 5yr Revenue CAGR -2.8%
  • 5yr EPS CAGR -12.9%
  • Revenue-Growth Years (5) 4/5

Cash Generation

Weight: 20%
A+ 95
  • 5yr FCF Margin 31.8%
  • 5yr FCF/NI Conversion 0.90x

Balance Sheet

Weight: 10%
A+ 100
  • Net Debt / EBITDA -1.01x
  • Interest Coverage (EBIT/Int) 120.42x
  • Altman Z-Score 6.60

Stability

Weight: 5%
C- 44
  • EPS Volatility (σ/μ) 0.67
  • Piotroski F-Score 5
  • Negative-Revenue Years (5) 1/5

Guru Flow

Curated superinvestor sentiment — not part of the AlphaQuality grade.
Holding

4 of 4 gurus held; 2 added; 2 trimmed.

Holders
4
Avg Δ position
+3931.7%
New buys
0
Full exits
0
As of Q1 2026